As a large proportion of people taking medications like Mounjaro, Ozempic and Wegovy for weight loss report consuming less ...

Mounjaro, a new treatment for Type 2 diabetes and obesity, has been launched in India after CDSCO approval. The drug, ...

As the obesity rate among people with type 1 diabetes rises, patients are taking popular weight loss drugs like Ozempic—and ...

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.

While the weight loss results were impressive across the group, the cost and side effects remain important barriers for ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay later under a partnership ...

Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...